Austedo (deutetrabenazine) is not a controlled substance. It is not listed on any DEA schedule, which means it does not carry the prescribing restrictions, refill limits, or monitoring requirements that apply to scheduled drugs like opioids or stimulants. Your doctor can prescribe it with a standard prescription, and pharmacies can dispense refills without the additional steps required for controlled medications.
Why Austedo Is Not Scheduled
The DEA schedules drugs based on their potential for abuse and dependence. Austedo works by blocking a protein on nerve cells that packages certain chemical messengers (dopamine, serotonin, norepinephrine) into storage compartments. The net effect is a reduction in these signaling chemicals in the brain. This mechanism does not produce euphoria, a high, or the kind of reinforcing effect that drives drug-seeking behavior.
During clinical development, the FDA reviewed Austedo specifically for abuse signals. No instances of euphoria, hallucinations, or elevated mood were found in the pivotal trials. Researchers also searched for any adverse events related to drug abuse, drug dependence, or drug withdrawal using standardized medical terminology and found none. Pill counts and compliance tracking confirmed that the only instances of non-compliance involved patients taking less medication than prescribed, not more. No overdoses occurred during the entire development program.
Tetrabenazine, the older drug that Austedo is based on, also has no history of abuse in post-marketing surveillance. The entire class of medications that work through this same mechanism remains unscheduled.
No Evidence of Dependence or Withdrawal
In one study, 44 patients who had been taking Austedo were taken off the drug for one week. Researchers monitored their heart rate and blood pressure, both sensitive indicators of a physical withdrawal state. None of these measurements showed the kind of elevation you would see if the body had become dependent on the drug. There was no suggestion of physiological withdrawal.
Tolerance was also not an issue. When researchers tracked individual patients’ doses over up to two years of use, the dose curves stayed stable. Patients did not need higher and higher doses to get the same benefit, which is a hallmark of drugs that carry dependence risk.
What Austedo Treats
Austedo is FDA-approved for two conditions: involuntary movements (chorea) associated with Huntington’s disease and tardive dyskinesia, a movement disorder that can develop as a side effect of certain psychiatric medications. Diagnosis of Huntington’s disease typically involves family history, a neurological exam, and genetic testing.
Serious Warnings to Know About
Although Austedo is not a controlled substance, it does carry a boxed warning, the most serious safety label the FDA assigns. In patients with Huntington’s disease, Austedo can increase the risk of depression and suicidal thoughts. This is partly because Huntington’s disease itself raises the baseline risk for depression and suicidality, and a drug that lowers dopamine and serotonin levels can compound that vulnerability.
Because of this risk, Austedo is contraindicated in patients who are suicidal or who have untreated or inadequately treated depression. Prescribers are expected to closely monitor for mood changes, and patients and caregivers are instructed to report any concerning behavioral shifts promptly. People with a history of depression or prior suicide attempts require particular caution.
The boxed warning does not make Austedo a controlled substance, but it does mean prescribers take extra care before writing the prescription and during ongoing treatment. In practice, this often means regular follow-up appointments to check on mood and mental health alongside the movement symptoms being treated.
How Prescriptions Work in Practice
Since Austedo is not scheduled, it follows standard prescription rules. Your doctor does not need to use a special prescription pad, and there are no DEA-imposed limits on how many refills you can receive. Pharmacies do not need to report dispensing to a prescription drug monitoring program the way they would for a Schedule II or III drug. You can get refills called in or sent electronically like most non-controlled medications.
That said, Austedo is a specialty medication with a high list price, so insurance companies often require prior authorization before covering it. This is an insurance requirement, not a legal or DEA-related restriction. Some patients access Austedo through specialty pharmacies as part of manufacturer support programs, but this is driven by cost management rather than controlled substance regulations.